Trending NewsTrending NewsNASDAQ:ARGX argenex (ARGX) Stock Price, News & Analysis $873.71 -2.05 (-0.23%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$871.02 -2.70 (-0.31%) As of 10/23/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About argenex Stock (NASDAQ:ARGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get argenex alerts:Sign Up Key Stats Today's Range$865.72▼$887.0750-Day Range$802.64▼$1,058.9052-Week Range$661.85▼$1,072.75Volume295,822 shsAverage Volume509,396 shsMarket Capitalization$54.95 billionP/E Ratio30.49Dividend YieldN/APrice Target$1,142.37Consensus RatingModerate Buy Company Overview argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms. argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis. The company also markets VYVGART Hytrulo, a subcutaneous formulation that combines efgartigimod alfa with recombinant human hyaluronidase PH20. Founded in 2008, argenx has expanded its operations across the United States, Europe and other international markets through a combination of research, clinical development and commercial activities. The company is led by Chief Executive Officer Tim Van Hauwermeiren and collaborates with academic, biotechnology and pharmaceutical partners to develop additional therapies for autoimmune conditions.AI Generated. May Contain Errors. Read More argenex Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreARGX MarketRank™: 4.74956358265 of 5 starsargenex scored higher than 95% of companies evaluated by MarketBeat, and ranked 14th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus Ratingargenex has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 23 buy ratings, 6 hold ratings, and no sell ratings.Upside Potentialargenex has a consensus price target of $1,142.37, representing about 30.7% upside from its current price of $873.71.Amount of Analyst Coverageargenex has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about argenex's stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth37.26% Earnings GrowthEarnings for argenex are expected to grow by 37.26% in the coming year, from $25.79 to $35.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of argenex is 30.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.83.Price to Earnings Ratio vs. SectorThe P/E ratio of argenex is 30.49, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 197.62.Price to Earnings Growth Ratioargenex has a PEG Ratio of 0.79. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share Ratioargenex has a P/B Ratio of 7.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.22% of the float of argenex has been sold short.Short Interest Ratio / Days to Coverargenex has a short interest ratio ("days to cover") of 4.94.Change versus previous monthShort interest in argenex has recently increased by 2.97%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend Yieldargenex does not currently pay a dividend.Dividend Growthargenex does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.43 News Sentimentargenex has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 28 news articles for argenex this week, compared to 8 articles on an average week.Search InterestOnly 15 people have searched for ARGX on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows6 people have added argenex to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, argenex insiders have not sold or bought any company stock.Percentage Held by Insiders2.43% of the stock of argenex is held by insiders.Percentage Held by Institutions60.32% of the stock of argenex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about argenex's insider trading history. Receive ARGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for argenex and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARGX Stock News HeadlinesArgenx (ENXTBR:ARGX) Stock Faces Margin Questions After Q3 Earnings4 hours ago | finance.yahoo.comArgenx Slumps On Mixed Third Quarter, Surprise Vyvgart Testing PlansOctober 24 at 9:50 AM | msn.comCrashGPT coming on Dec. 18 …Sam Altman is expected to reveal a confidential OpenAI document around 4 p.m. on Dec. 18, just weeks before a potential IPO. The disclosure could trigger a 40 trillion dollar wealth shift. Altman himself has warned that someone is going to lose a phenomenal amount of money while others gain just as much.October 24 at 1:00 AM | Weiss Ratings (Ad)argenx (NASDAQ: ARGX) net sales jump 54% as pipeline milestones stack upOctober 24 at 4:36 AM | americanbankingnews.comargenx (ARGX) Q3 2026 Earnings Call TranscriptOctober 23 at 9:19 AM | finance.yahoo.comargenx: 3 Key Takeaways for Long-Term InvestorsOctober 23 at 7:05 AM | fool.comargenx SE 2026 Q3 - Results - Earnings Call PresentationOctober 23 at 1:02 AM | seekingalpha.comargenx Reports Third Quarter 2026 Financial Results and Provides Business UpdateOctober 22 at 2:23 PM | markets.businessinsider.comSee More Headlines ARGX Stock Analysis - Frequently Asked Questions How have ARGX shares performed this year? argenex's stock was trading at $840.95 at the start of the year. Since then, ARGX shares have increased by 3.9% and is now trading at $873.71. How were argenex's earnings last quarter? argenex SE (NASDAQ:ARGX) posted its earnings results on Friday, October, 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $7.44 by $0.36. The company had revenue of $1.75 billion for the quarter. argenex had a trailing twelve-month return on equity of 35.77% and a net margin of 31.66%. Read the conference call transcript. When did argenex IPO? argenex (ARGX) raised $97 million in an initial public offering on Thursday, May 18th 2017. The company issued 5,865,000 shares at $16.62 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are argenex's major shareholders? Top institutional investors of argenex include Assenagon Asset Management S.A. (0.06%), Perpetual Ltd (0.04%), Crossmark Global Holdings Inc. (0.01%) and Gunderson Capital Management LLC (0.01%). How do I buy shares of argenex? Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of argenex own? Based on aggregate information from My MarketBeat watchlists, some other companies that argenex investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Broadcom (AVGO), Palantir Technologies (PLTR), Palo Alto Networks (PANW) and CrowdStrike (CRWD). Company Calendar Last Earnings10/23/2026Today10/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, ARGX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ARGX Previous SymbolNASDAQ:ARGX CIK1697862 Webwww.argenx.com Phone(176) 303-0488FaxN/AEmployees1,863Year Founded2008Price Target and Rating Average Price Target for argenex$1,142.37 High Price Target$1,400.00 Low Price Target$861.00 Potential Upside/Downside+30.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage30 Analysts Profitability EPS (Trailing Twelve Months)$28.66 Trailing P/E Ratio30.49 Forward P/E Ratio33.88 P/E Growth0.79Net Income$1.29 billion Net Margins31.66% Pretax Margin32.80% Return on Equity35.77% Return on Assets30.09% Debt Debt-to-Equity RatioN/A Current Ratio5.12 Quick Ratio4.89 Sales & Book Value Annual Sales$4.25 billion Price / Sales12.93 Cash Flow$21.33 per share Price / Cash Flow40.96 Book Value$118.34 per share Price / Book7.38Miscellaneous Outstanding Shares62,890,000Free Float61,358,000Market Cap$54.95 billion OptionableOptionable Beta0.44 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ARGX) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredMissed this in 2024? Here’s your second chanceIn April 2024, gold had gone nowhere for 13 years - then it surged to a record high, more than doubling in val...Traders Agency | SponsoredSpaceX is worth trillions. This one's $14.It is not SpaceX, Tesla, Starlink, or Neuralink. But Elon's rocket company shows up in this stock's paperwork,...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThe data center backlash is creating a rare investing opportunityA new Gallup poll shows 70% of Americans want AI data centers kept out of their communities - and futurist Geo...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding argenex SE Please log in to your account or sign up in order to add this asset to your watchlist. Share argenex With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
